Nomogram for predicting overall survival in children with neuroblastoma based on SEER database

다국어 초록 (Multilingual Abstract)

Purpose: This study was performed to establish and validate a nomogram for predicting the overall survival in children with neuroblastoma.
Methods: The latest clinical data of neuroblastoma in Surveillance, Epidemiology, and End Results (SEER) database was extracted from 2000 to 2016. The cases included were randomly divided into training and validation cohorts. The survival curves were drawn with a Kaplan-Meier estimator to investigate the influences of certain single factors on overall survival.
Also, least absolute shrinkage and selection operator regression was applied to further select the prognostic variables for neuroblastoma. Additionally, receiver operating characteristic (ROC) curves and calibration curves were used to evaluate the accuracy of the nomogram.
Results: In total, 1,262 patients were collected and 8 independent prognostic factors were achieved, including patients’ age, sex, race, tumor grade, radiotherapy, chemotherapy, tumor site, and tumor size. Then we constructed a nomogram by using the data of the training cohort with 886 cases. Subsequently, the nomogram was validated internally and externally with 886 and 376 cases, respectively. The internal validation revealed that the area under the curves (AUC) of ROC curves of 1-, 3-, and 5-year overall survival were 0.69, 0.78, and 0.81, respectively. Accordingly, the external validation also showed that the AUC of 1-, 3-, and 5-year overall survival were all ≥0.69. Both methods of validation demonstrated that the predictive calibration curves were consistent with standard curves.
Conclusion: The nomogram possess the potential to be a new tool in predicting the survival rate of neuroblastoma patients.

참고문헌 (Reference)

1 Swift CC, "Updates in diagnosis, management, and treatment of neuroblastoma" 38 : 566-580, 2018

2 Tibshirani R, "The lasso method for variable selection in the Cox model" 16 : 385-395, 1997

3 Rickman DS, "The expanding world of N-MYC-driven tumors" 8 : 150-163, 2018

4 Morgenstern DA, "The challenge of defining “ultra-high-risk”neuroblastoma" 66 : e27556-, 2019

5 Cohn SL, "The International Neuroblastoma Risk Group(INRG)classification system : an INRG Task Force report" 27 : 289-297, 2009

6 Luz Jubierre, "Targeting of epigenetic regulators in neuroblastoma" 생화학분자생물학회 50 : 1-12, 2018

7 Zareifar S, "Successful treatment of refractory metastatic neuroblastoma with panobinostat in combination with chemotherapy agents and iodine-131-meta-iodobenzylguanidine therapy" 26 : 481-486, 2020

8 Park JR, "Revisions to the international neuroblastoma response criteria : a consensus statement from the National Cancer Institute clinical trials planning meeting" 35 : 2580-2587, 2017

9 Brodeur GM, "Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment" 11 : 1466-1477, 1993

10 Jiang Y, "Radiomics signature on computed tomography imaging : association with lymph node metastasis in patients with gastric cancer" 9 : 340-, 2019

11 Mohler JL, "Prostate Cancer, Version 2. 2019, NCCN Clinical Practice Guidelines in Oncology" 17 : 479-505, 2019

12 Hu J, "Pretreatment risk management of a novel nomogram model for prediction of thoracoabdominal extrahepatic metastasis in primary hepatic carcinoma" 17 : 117-, 2019

13 Cheng-Xiang Guo, "Prediction of postoperative pancreatic fistula using a nomogram based on the updated definition" 대한외과학회 98 (98): 72-81, 2020

14 PDQ Pediatric Treatment Editorial Board, "PDQ Cancer Information Summaries" National Cancer Institute (US) 2002

15 Hu CY, "Nomograms for predicting long-term overall survival and cancerspecific survival in lip squamous cell carcinoma : a population-based study" 8 : 4032-4042, 2019

16 Liu G, "Nomograms for estimating survival in patients with papillary thyroid cancer after surgery" 11 : 3535-3544, 2019

17 Meena JP, "Neuroblastoma in a developing country : miles to go" 86 : 403-405, 2019

18 Louis CU, "Neuroblastoma : molecular pathogenesis and therapy" 66 : 49-63, 2015

19 Matthay KK, "Neuroblastoma" 2 : 16078-, 2016

20 Yao W, "Long-term prognosis of low-risk neuroblastoma treated by surgery alone : an experience from a single institution of China" 15 : 148-152, 2019

21 Han Y, "Integrative analysis based on survival associated co-expression gene modules for predicting Neuroblastoma patients’ survival time" 14 : 4-, 2019

22 Huang L, "Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma : a large international population-based cohort study" 17 : 66-, 2019

23 Pastor ER, "Current management of neuroblastoma and future direction" 138 : 38-43, 2019

24 London WB, "Clinical and biologic features predictive of survival after relapse of neuroblastoma : a report from the International Neuroblastoma Risk Group project" 29 : 3286-3292, 2011

25 Valter K, "Cell death-based treatment of neuroblastoma" 9 : 113-, 2018

26 Pinto NR, "Advances in risk classification and treatment strategies for neuroblastoma" 33 : 3008-3017, 2015

27 Herd F, "A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma" 111 : 50-58, 2019

28 Li X, "A prognostic nomogram for neuroblastoma in children" 7 : e7316-, 2019

29 Xie Y, "A 3-protein expression signature of neuroblastoma for outcome prediction" 42 : 1027-1035, 2018